Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

References

• RodeghieroFStasiRGernsheimerTStandardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood2009113112386239319005182
   PubMed Web of Science ®Google Scholar
• CinesDBBusselJBHow I treat idiopathic thrombocytopenic purpura (ITP)Blood200510672244225115941913
   PubMed Web of Science ®Google Scholar
• LiSMolonyJTCetinKWasserJSAltomareIRate of bleeding-rated episodes (BREs) in elderly patients with primary immune thrombocytopenia (ITP): A population-based retrospective cohort study using medicare 20% sample data. Clinically Relevant AbstractASH Annual Meeting and Exposition2015Orlando, FL
   Google Scholar
• BranehogIKuttiJWeinfeldAPlatelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP)Br J Haematol19742711271434212246
   PubMed Web of Science ®Google Scholar
• BallemPJSegalGMStrattonJRGernsheimerTAdamsonJWSlichterSJMechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearanceJ Clin Invest198780133403597777
   PubMed Web of Science ®Google Scholar
• FoxJEPlatelet activation: new aspectsHaemostasis199626Suppl 41021318979117
   PubMedGoogle Scholar
• MachlusKRItalianoJEJrThe incredible journey: From megakaryocyte development to platelet formationJ Cell Biol2013201678579623751492
   PubMed Web of Science ®Google Scholar
• KaushanskyKThrombopoietin: the primary regulator of platelet productionBlood19958624194317605981
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: Modified Risk Evaluation and Mitigation Strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag)2011 Available from: http://www.fda.gov/Drugs/Drug-Safety/ucm280165.htm#Accessed December 28, 2015
   Google Scholar
• Nplate Prescribing Information and Medication Guide2011 Available from: http://www.nplatehcp.com/nplate/nplate-nexusAccessed December 28, 2015
   Google Scholar
• HicksLKBeringHCarsonKRThe ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to questionBlood2013122243879388324307720
   PubMed Web of Science ®Google Scholar
• GhanimaWGodeauBCinesDBBusselJBHow I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentBlood2012120596096922740443
   PubMed Web of Science ®Google Scholar
• MitchellWBBusselJBThrombopoietin receptor agonists: a critical reviewSemin Hematol2015521465225578419
   PubMed Web of Science ®Google Scholar
• CwirlaSEBalasubramanianPDuffinDJPeptide agonist of the thrombopoietin receptor as potent as the natural cytokineScience19972765319169616999180079
   PubMed Web of Science ®Google Scholar
• KuterDJBegleyCGRecombinant human thrombopoietin: basic biology and evaluation of clinical studiesBlood2002100103457346912411315
   PubMed Web of Science ®Google Scholar
• BroudyVCLinNLAMG531 stimulates megakaryopoiesis in vitro by binding to MplCytokine2004252526014693160
   PubMed Web of Science ®Google Scholar
• BroudyVCLinNLKaushanskyKThrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases mega-karyocyte ploidy in vitroBlood1995857171917267535585
   PubMed Web of Science ®Google Scholar
• CurraoMBalduiniCLBalduiniAHigh doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytesPloS One201381e5472323359807
   PubMed Web of Science ®Google Scholar
• SunYNArendsRSmithsonAWatsonANicholJLA novel thrombopoiesis-stimulating agent, AMG 531: Pharmacokinetics and pharmacodynamics in FcRn knock-out and wild type miceBlood2005106357516076869
   PubMed Web of Science ®Google Scholar
• WangBNicholJLSullivanJTPharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligandClin Pharmacol Ther200476662863815592334
   PubMed Web of Science ®Google Scholar
• BusselJBKuterDJGeorgeJNAMG 531, a thrombopoiesis-stimulating protein, for chronic ITPN Engl J Med2006355161672168117050891
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBLyonsRMEfficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialLancet2008371961039540318242413
   PubMed Web of Science ®Google Scholar
• NewlandACaulierMTKappers-KlunneMAn open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpuraBr J Haematol2006135454755317061981
   PubMed Web of Science ®Google Scholar
• ShirasugiYAndoKMiyazakiKRomiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trialInt J Hematol2011941718021706145
   PubMed Web of Science ®Google Scholar
• RuggeriMTosettoAPalandriFThrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factorsJ Thromb Haemost20141281266127324942752
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBNewlandALong-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyBr J Haematol2013161341142323432528
   PubMed Web of Science ®Google Scholar
• BrynesRKOraziATheodoreDEvaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND studyAm J Hematol201590759860125801698
   PubMed Web of Science ®Google Scholar
• CinesDBGernsheimerTWasserJIntegrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostimInt J Hematol2015102325927026201709
   PubMed Web of Science ®Google Scholar
• BusselJBHsiehLBuchananGRLong-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP)Pediatr Blood Cancer Epub20141024
   Web of Science ®Google Scholar
• BusselJBBuchananGRNugentDJA randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopeniaBlood20111181283621502541
   PubMed Web of Science ®Google Scholar
• ElalfyMSAbdelmaksoudAAEltonbaryKYRomiplostim in children with chronic refractory ITP: randomized placebo controlled studyAnn Hematol201190111341134421318572
   PubMed Web of Science ®Google Scholar
• PasquetMAladjidiNGuitonCRomiplostim in children with chronic immune thrombocytopenia (ITP): the French experienceBr J Haematol2014164226627124152194
   PubMed Web of Science ®Google Scholar
• ChoeMJPackerCDSevere romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITPAnn Pharmacother201549114014425325908
   PubMed Web of Science ®Google Scholar
• CarpenedoMCantoniSCocciniVPoglianiEMCairoliRResponse loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case seriesEur J Haematol Epub20151231
   Web of Science ®Google Scholar
• BusselJBWangXLopezAEisenMCase study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostimHematology Epub201587
   Web of Science ®Google Scholar
• Truven Health Analytics. Micromedex solutions. [homepage on the Internet] Available from URL: http://micromedex.com/Accessed November 1, 2016
   Google Scholar